BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 32897123)

  • 21. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
    Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
    Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.
    Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi YB; Shou JZ; Zhou AP; Li CL; Ma JH; Wang JW; Sun Y
    Chin Med J (Engl); 2016 Mar; 129(5):530-5. PubMed ID: 26904986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
    Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
    Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
    Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma.
    Andrews JR; Lohse CM; Boorjian SA; Leibovich BC; Thompson H; Costello BA; Bhindi B
    Urol Oncol; 2022 Apr; 40(4):166.e1-166.e8. PubMed ID: 35168879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study.
    Okita K; Hatakeyama S; Naito S; Numakura K; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Nishiyama H; Ito A; Kojima Y; Habuchi T; Obara W; Tsuchiya N; Ohyama C
    Urol Oncol; 2021 Dec; 39(12):836.e11-836.e17. PubMed ID: 34544649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma.
    Roussel E; Campi R; Larcher A; Verbiest A; Antonelli A; Palumbo C; Derweesh I; Ghali F; Bradshaw A; Meagher MF; Heck M; Amiel T; Kriegmair MC; Rubio J; Musquera M; D'Anna M; Autorino R; Guruli G; Veccia A; Linares-Espinos E; Van Bruwaene S; Hevia V; Porpiglia F; Checcucci E; Minervini A; Mari A; Pavan N; Claps F; Marchioni M; Capitanio U; Beuselinck B; Mir MC; Albersen M;
    Eur Urol Oncol; 2020 Aug; 3(4):523-529. PubMed ID: 32414697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach.
    Hall ME; Bhindi B; Luckenbaugh AN; Laviana AA; Moses KA; Satkunasivam R; Rini B; Klaassen Z; Wallis CJD
    Cancer Causes Control; 2021 Jul; 32(7):675-680. PubMed ID: 33963938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale?].
    Gilbert N; Merseburger AS; Kramer MW
    Urologe A; 2017 May; 56(5):604-609. PubMed ID: 28314973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.
    Gross EE; Li M; Yin M; Orcutt D; Hussey D; Trott E; Holt SK; Dwyer ER; Kramer J; Oliva K; Gore JL; Schade GR; Lin DW; Tykodi SS; Hall ET; Thompson JA; Parikh A; Yang Y; Collier KA; Miah A; Mori-Vogt S; Hinkley M; Mortazavi A; Monk P; Folefac E; Clinton SK; Psutka SP
    Urol Oncol; 2023 Jan; 41(1):51.e25-51.e31. PubMed ID: 36441070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study.
    Kato R; Naito S; Numakura K; Hatakeyama S; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Ohyama C; Habuchi T; Tsuchiya N; Obara W
    Int J Clin Oncol; 2022 Mar; 27(3):563-573. PubMed ID: 34973106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
    Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
    Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
    Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
    World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
    Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
    Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic renal cell carcinoma patients of T4 stage who are in status of N1 stage or older than 76 years cannot benefit from cytoreductive nephrectomy.
    Zhang Z; Wu H; Yang T; Wu Y; Yu N; Xu Z
    BMC Cancer; 2020 Sep; 20(1):844. PubMed ID: 32883242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.
    Faiena I; Salmasi A; Lenis AT; Donin NM; Johnson DC; Bachour K; Drakaki A; Belldegrun AS; Pantuck AJ; Chamie K
    Urol Oncol; 2018 Feb; 36(2):79.e19-79.e26. PubMed ID: 29103965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis.
    Chen B; Li J; Huang Y; Tang B; Jiang J; Chen Z; Li J; Wang P; Cao D; Liu L; Wei Q
    Int J Surg; 2023 Apr; 109(4):982-994. PubMed ID: 36974696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
    Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
    Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
    Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
    Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
    Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
    Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.